Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses
Cytotoxic therapies such as chemotherapy and antibody-drug conjugates (ADCs) kill tumor cells directly but are limited by resistance, dose-limiting toxicity, and failure to induce durable antitumor immunity. Here we show that tumor-associated antigen (TAA)-targeted CD28 bispecific antibodies (TAAxCD28) convert cytotoxic agents into drivers of durable antitumor immunity. In humanized mouse models, combining the HER2-directed ADC trastuzumab deruxtecan (Tras-DXd) with TAAxCD28 antibodies enhances tumor rejection and promotes durable immune memory in Tras-DXd-resistant cancers, and comparable synergy is observed with 5-fluorouracil (5-FU). This therapeutic strategy allows lower or less frequent cytotoxic drug dosing, potentially limiting systemic toxicity. Mechanistically, TAAxCD28 antibodies promote the activation and expansion of clonally-restricted tumor CD8+ T cells, and adding ADCs or chemotherapy sustains this activation while preserving a naïve/stem-like pool of tumor-specific CD8+ T cells with a diversified T cell receptor repertoire. Each cytotoxic agent supports this T cell activity through a separate innate mechanism: Tras-DXd expands and activates conventional dendritic cells, whereas 5-FU reprograms suppressive myeloid cells toward an immunostimulatory phenotype. Together, these findings support pairing cytotoxic agents with TAAxCD28 bispecifics to overcome resistance and improve long-term tumor control in refractory cancers. TAA×CD28 costimulatory bispecific antibodies are a class of immunotherapeutics that provide tumor-targeted CD28 costimulation to T cells by crosslinking CD28 on T cells to a tumor-associated antigen (TAA) expressed on tumor cells. Here, the authors show that cytotoxic therapies reprogram the tumor microenvironment and augment the antitumor immunity induced by TAA×CD28 bispecifics.
Authors
- Wei‐Yi Cheng (ORCID: https://orcid.org/0000-0002-7588-298X)
- Jennifer Finney (ORCID: https://orcid.org/0000-0001-9530-2826)
- Allen Y. Leary (ORCID: https://orcid.org/0009-0008-6546-2237)
- Jacob Lowy
- Frank A. Seebach
- Kamilah Ryan
- Dylan Kwart
- Melissa Divya Mathias (ORCID: https://orcid.org/0000-0001-6026-601X)
- Christopher Daly (ORCID: https://orcid.org/0000-0003-3800-8174)
- Israel Lowy (ORCID: https://orcid.org/0000-0002-5421-2485)
- Aynur Hermann (ORCID: https://orcid.org/0000-0002-5426-7777)
- Lauric Haber (ORCID: https://orcid.org/0000-0002-9222-9843)
- Jeremy S. Rabinowitz (ORCID: https://orcid.org/0000-0002-6981-6863)
- Albert Canturri (ORCID: https://orcid.org/0000-0002-5204-0624)
- Qiaozhi Wei (ORCID: https://orcid.org/0000-0003-3062-5071)
- Erica Ullman (ORCID: https://orcid.org/0000-0001-6996-9053)
- Jacqueline J. Warsaw (ORCID: https://orcid.org/0009-0008-2410-0598)
- Dharani K. Ajithdoss (ORCID: https://orcid.org/0000-0001-5007-1163)
- Patrick Poon (ORCID: https://orcid.org/0000-0003-2243-8436)
- Andria Skinner
- Jacquelynn Golubov (ORCID: https://orcid.org/0000-0003-2382-657X)
- Erin Paul (ORCID: https://orcid.org/0000-0001-7007-699X)
- William T. Poueymirou (ORCID: https://orcid.org/0000-0003-3164-7248)
- Min Ni (ORCID: https://orcid.org/0000-0001-6382-0848)
- Dimitris Skokos (ORCID: https://orcid.org/0000-0003-1196-3139)
- Christina Adler (ORCID: https://orcid.org/0009-0005-2557-6246)
- Bei Wang (ORCID: https://orcid.org/0000-0003-3002-3302)
- Namita T. Gupta (ORCID: https://orcid.org/0000-0002-4517-1546)
- Andrew J. Murphy (ORCID: https://orcid.org/0000-0003-4152-4081)
- John C. Lin (ORCID: https://orcid.org/0009-0000-7780-8006)
- Matthew Fury
- Ciara Torres
- Eric Smith
- Nicole Stokes Oristian
- William Olson
Institutions
- Regeneron (United States) (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1038/s41467-026-79192-3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00